Simultaneous whole-body 18 F-FDG PET-MRI in primary staging of breast cancer: A pilot study

Taneja, Sangeeta; Jena, Amarnath; Goel, Reema; Sarin, Ramesh; Kaul, Shibban K

doi:10.1016/j.ejrad.2014.09.008

Cited by 75 publications

(58 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14,15 The recent introduction of integrated PET/MRI systems enables now a simultaneous high-quality assessment of the local tumor extent and metastatic spread, by combining the diagnostic advantages of MRI and PET. 16,17 Accordingly, the aim of our study was to evaluate the diagnostic performance of integrated PET/MRI of the breast for local tumor and nodal staging of patients with primary breast cancer in comparison to PET/CT and MRI. Furthermore, we investigated whether PET/MRI might improve diagnostic accuracy for the identification and characterization of primary breast tumors.…”

mentioning

confidence: 99%

Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer

Grueneisen

Nagarajah

Buchbender

et al. 2015

Investigative Radiology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer

Grueneisen

Nagarajah

Buchbender

et al. 2015

Investigative Radiology

View full text Add to dashboard Cite

show abstract

“…Similar to our results, PET shows best results for axillary lymph node staging. On the contrary, Taneja and colleagues showed a lower sensitivity on PET (60%) than on MRI (93.3%) for detection of axillary lymph nodes with PET/MRI [27]. A possible explanation for the lower PET detection rate is that PET/ MRI scans in the study of Taneja might have been made during NAC treatment (this was not specified).…”

Section: Discussionmentioning

confidence: 58%

Hybrid 18F–FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy

Goorts

Vöö

Nijnatten

et al. 2017

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Our purpose in this study was to assess the added clinical value of hybrid 18 F-FDG-PET/MRI compared to conventional imaging for locoregional staging in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Methods In this prospective study, primary invasive cT2-4 N0 or cT1-4 N+ breast cancer patients undergoing NAC were included. A PET/MRI breast protocol was performed before treatment. MR images were evaluated by a breast radiologist, blinded for PET images. PET images were evaluated by a nuclear physician. Afterwards, a combined PET/MRI report was written. PET/MRI staging was compared to conventional imaging, i.e., mammography, ultrasound and MRI. The proportion of patients with a modified treatment plan based on PET/MRI findings was analyzed.Results A total of 40 patients was included. PET/MRI was of added clinical value in 20.0% (8/40) of patients, changing the treatment plan in 10% and confirming the malignancy of suspicious lesions on MRI in another 10%. In seven (17.5%) patients radiotherapy fields were extended because of additional or affirmative PET/MRI findings being lymph node metastases (n = 5) and sternal bone metastases (n = 2). In one (2.5%) patient radiotherapy fields were reduced because of fewer lymph node metastases on PET/MRI compared to conventional imaging. Interestingly, all treatment changes were based on differences in number of lymph nodes suspicious for metastasis or number of distant metastasis, whereas differences in intramammary tumor extent were not observed. Conclusion Prior to NAC, PET/MRI shows promising results for locoregional staging compared to conventional imaging, changing the treatment plan in 10% of patients and potentially replacing PET/CT or tissue sampling in another 10% of patients.

show abstract

“…So far, only very few studies based on relatively small sample sizes have addressed the clinical workflow, feasibility, and optimized PET/MRI protocols in oncology [76]- [78]. Although some authors report no added diagnostic benefit in comparison with PET/CT or MRI [76], [79], [80], [81], others describe added value in selected cases [82]- [84]. During the past two years, there has been only a slow increase in the rate of new PET/MRI system installations, mainly owing to lack of clearly defined applications, and currently, there is little evidence to validate key applications based on the experience of multiple centers.…”

Section: Clinical Applications Of Pet/mrimentioning

confidence: 96%

The Promise of Hybrid PET\/MRI: Technical advances and clinical applications

Zaidi

Becker

2016

IEEE Signal Process. Mag.

View full text Add to dashboard Cite

D uring the last few decades, positron emission tomography (PET)-based molecular imaging has advanced eleg antly and steadily gained importance in the clinical and research arenas. However, the lack of structural information provided by this imaging modality motivated its correlation with structural imaging techniques such as X-ray computed tomography (CT) or magnetic resonance imaging (MRI), which are well established in the clinical setting. The additional capability of simultaneous acquisition of PET and MRI data bridges the gap between molecular and morphologic diagnoses. Since diagnostic imaging methods evolve from the anatomical to the molecular level, the mission of multimodal and multiparametric imaging increasingly becomes more essential. Since 2010, whole-body hybrid PET/MRI has been investigated in the clinical setting for clinical diagnosis and staging, treatment response monitoring, and radiation therapy treatment planning of a wide range of malignancies. However, quantitative PET/MRI is still challenged by the lack of accurate and robust attenuation and motion compensation strategies to enable the production of artifact-free and quantitative PET images. This article briefly summarizes the historical development of PET/MRI and gives Technical advances and clinical applications ©graphic stock 68 IEEE SIgnal ProcESSIng MagazInE | May 2016 | an overview of the state of the art and recent advances in the design and construction of clinical systems. Progress in quantitative imaging, including MRI-guided image reconstruction and correction, and potential clinical applications of this novel technology are also discussed.

show abstract

Simultaneous whole-body 18 F-FDG PET-MRI in primary staging of breast cancer: A pilot study

Cited by 75 publications

References 26 publications

Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer

Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer

Hybrid 18F–FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy

The Promise of Hybrid PET\/MRI: Technical advances and clinical applications

Contact Info

Product

Resources

About